Investigational drug · Phase 2
STAR0602
Also called: Invikafusp
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "STAR0602"
First trial start
2023
Jan 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STAR0602", any sponsor or status.
Conditions studied
As listed on its trial records.
- Triple Negative Locally Advanced Non-resectable Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
- Advanced Solid Tumors
- Genital Neoplasm, Female
- Urogenital Neoplasms
- Lung Neoplasm
- Neoplasms by Site
- Papillomavirus Infection
- Epstein-Barr Virus Infections
- Carcinoma
Approved drugs for the same conditions: Breast cancer · Oncology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "STAR0602" as an intervention, largest first.
Marengo Therapeutics, Inc.Industry
NCT05592626 · 366 participants (planned) · Start Jan 4, 2023 · Primary completion Sep 2027
Drug: STAR0602 · For: Advanced Solid Tumors; Genital Neoplasm, Female; Urogenital Neoplasms and 11 more
Sites: Sacramento, California; Celebration, Florida; Miami, Florida · 19 sites in all
- STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic CarcinomaNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07902921 · 67 participants (planned) · Start Nov 24, 2026 · Primary completion Dec 31, 2029
Drug: STAR0602; Nivolumab · For: NSCLC; Non-Small Cell Lung Cancer; Lung Cancer and 7 more
Sites: Bethesda, Maryland
Marengo Therapeutics, Inc.Industry
NCT06827613 · 50 participants (planned) · Start Mar 24, 2025 · Primary completion Jan 2027
Drug: STAR0602; Sacituzumab Govitecan (SG) · For: Triple Negative Locally Advanced Non-resectable Breast Cancer; HR+, HER2-, Advanced Breast Cancer
Sites: Los Angeles, California; Boston, Massachusetts; Columbus, Ohio · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.
Sullivan RJ, Tschernia NP, Friedman CF, et al. · Nat Med 2026
- PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.
Santiago-Sanchez G, Rosato F, Fabian KP, et al. · J Immunother Cancer 2026
- Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models.
Lee JK, Fabian KP, Santiago-Sanchez GS, et al. · Front Immunol 2026
- Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models.
Rosato F, Santiago-Sanchez G, Fabian KP, et al. · J Immunother Cancer 2025
- A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity.
Hsu J, Donahue RN, Katragadda M, et al. · Sci Transl Med 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.